The Evolving Treatment Landscape for EGFR-Mutated NSCLC - Certificate of Completion
Non-small cell lung carcinoma (NSCLC) comprises approximately 80% of all lung cancers and encompasses several histologic types of tumour including adenocarcinoma, squamous cell carcinoma (SCC) and large cell carcinoma. Over time, there has been a marked change in the distribution of NSCLC across the three histological subgroups – mainly a decrease in the proportion of SCC. This may be explained by changes in characteristics of cigarettes and consequent changes in the inhaled dose of carcinogens.
Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD). The program has been reviewed and approved by the Clinical Oncology Society of Australia. This interactive online learning activity is valued at 1 Hour(s) of continuing education.
Professor Michael Boyer AM
MBBS, FRACP, PhD
Medical Oncologist, Chris O’Brien Lifehouse, NSW
Professor Paul Mitchell
MBCHB, MD, PhD, FRACP
Medical Oncologist, Austin Health, VIC
On completion of this program, participants will be better able to:
- Recall clinical presentations of non-small cell lung cancer (NSCLC).
- Compare first-, second- and third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of NSCLC.
- Evaluate clinical trial data on treatment of EGFR-positive NSCLC, considering progression-free survival (PFS) and overall survival (OS).
- Better manage adverse events associated with EGFR TKIs and improve the tolerability profile through dose modification where appropriate.